Indivior Pharmaceuticals, Inc.INDVEarnings & Financial Report
Nasdaq
Indivior is an American pharmaceuticals company. Established as a division of Reckitt Benckiser in 1994 and demerged from that company in December 2014, it is focussed on substitution products for opioid addiction. It is listed on the London Stock Exchange and on the NASDAQ Global Select Market.
NextMar 13, 2026
INDV Q3 2026 Key Financial Metrics
売上高
$314.0M
粗利益
$230.0M
営業利益
$43.0M
純利益
$42.0M
粗利益率
73.2%
営業利益率
13.7%
純利益率
13.4%
前年比成長
N/A
EPS
$0.33
資金フロー
Indivior Pharmaceuticals, Inc. Q3 2026 Financial Summary
Indivior Pharmaceuticals, Inc. reported revenue of $314.0M for Q3 2026, with a net profit of $42.0M (13.4% margin). Cost of goods sold was $84.0M, operating expenses totaled $187.0M.
Key Financial Metrics
| Total Revenue | $314.0M |
|---|---|
| Net Profit | $42.0M |
| Gross Margin | 73.2% |
| Operating Margin | 13.7% |
| Report Period | Q3 2026 |
損益計算書
| Q1 2024 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|
| 売上高 | $284.0M | $266.0M | $302.0M | $314.0M |
| 前年比成長 | N/A | N/A | N/A | N/A |
貸借対照表
| Q1 2024 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|
| 総資産 | N/A | $1.38B | $1.45B | $1.42B |
| 総負債 | N/A | $1.66B | $1.71B | $1.62B |
| 株主資本 | $-161.0M | $-285.0M | $-257.0M | $-207.0M |
キャッシュフロー
| Q1 2024 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|
| 営業CF | $-37.0M | $75.0M | $158.0M | $-39.0M |